{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:45:52Z","timestamp":1767066352423,"version":"3.32.0"},"reference-count":27,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It is of much interest to understand the efficacy of abiraterone acetate (AA) in routine clinical practice. We assessed the clinical outcome of AA in patients with metastatic castration\u2010resistant prostate cancer (mCRPC) and determined clinical factors associated with AA treatment duration in real\u2010world setting. This real\u2010world cohort consisted of 93 patients with mCRPC treated with AA in Thailand (58.1%) and Malaysia (41.9%). Primary endpoints were overall survival (OS) and biochemical progression\u2010free survival (bPFS). Secondary endpoints were predictors associated with AA treatment duration evaluated with Cox proportional hazards regression. Around 74% were chemotherapy\u2010na\u00efve. The median AA treatment duration was 10\u00a0months (IQR 5.6\u201017.1). Malaysians had a relatively lower median OS and bPFS (OS 17.8\u00a0months; 95% CI 6.4\u201029.1, bPFS 10.4\u00a0months; 95% CI 8.8\u201012.0) compared to Thais (OS 27.0\u00a0months; 95% CI 11.3\u201042.7, bPFS 14.0\u00a0months; 95% CI 5.8\u201022.2), although it did not achieve statistical significance (<jats:italic>P<\/jats:italic>\u00a0&gt;\u00a0.05). Patients with longer AA treatment duration (&gt;10\u00a0months) had lower risk of death and longer bPFS, compared to those with shorter AA treatment duration (\u226410\u00a0months) (hazard ratio [HR] 0.10, 95% CI 0.05\u20100.22 and HR 0.13, 95% CI 0.06\u20100.25, respectively). Multivariable analysis showed that PSA at AA initiation, presence of PSA response and chemotherapy\u2010naive were independently associated with AA duration (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.05). Abiraterone acetate is well\u2010tolerated in the Southeast Asian cohort with comparable survival benefits to other Asian populations in real\u2010world setting. Lower PSA levels at AA initiation, presence of PSA response, and chemotherapy\u2010naive were significant in determining AA treatment duration.<\/jats:p>","DOI":"10.1002\/cam4.3101","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T10:23:41Z","timestamp":1588760621000},"page":"4613-4621","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration\u2010resistant prostate cancer: Real\u2010world experience in the Southeast Asian cohort"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7501-1834","authenticated-orcid":false,"given":"Jasmine","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Surgery Faculty of Medicine University of Malaya Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akara","family":"Amantakul","sequence":"additional","affiliation":[{"name":"Department of Surgery Faculty of Medicine Chiang Mai University Chiang Mai Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Shariff","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Faculty of Medicine University of Malaya Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bannakij","family":"Lojanapiwat","sequence":"additional","affiliation":[{"name":"Department of Surgery Faculty of Medicine Chiang Mai University Chiang Mai Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adlinda","family":"Alip","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Faculty of Medicine University of Malaya Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng Aik","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Surgery Faculty of Medicine University of Malaya Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankaran","family":"Thevarajah","sequence":"additional","affiliation":[{"name":"Department of Urology Queen Elizabeth Hospital Kota Kinabalu Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firdaus","family":"Ahmayuddin","sequence":"additional","affiliation":[{"name":"Department of Urology Queen Elizabeth Hospital Kota Kinabalu Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeline","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology Sabah Women and Children Hospital Kota Kinabalu Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supon","family":"Sriplakich","sequence":"additional","affiliation":[{"name":"Department of Surgery Faculty of Medicine Chiang Mai University Chiang Mai Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaraspong","family":"Vuthiwong","sequence":"additional","affiliation":[{"name":"Department of Surgery Faculty of Medicine Chiang Mai University Chiang Mai Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora Li Tze","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology Sabah Women and Children Hospital Kota Kinabalu Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marniza","family":"Saad","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Faculty of Medicine University of Malaya Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"293","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins C","year":"1941","journal-title":"Cancer Res"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2009.03.016"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"e_1_2_9_5_1","unstructured":"NCCN clinical practice guidelines in oncology. Prostate Cancer. Version 2 2019."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14807"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-016-0132-z"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.06.010"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20160082"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.055"},{"issue":"291","key":"e_1_2_9_13_1","first-page":"e1","article-title":"A single\u2010center experience with abiraterone as treatment for metastatic castration\u2010resistant prostate cancer","volume":"34","author":"Thortzen A","year":"2016","journal-title":"Urol Oncol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3755-x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_85_18"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13241"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5280-6"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2016.31"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu149"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu148"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.03.010"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds119"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.01.018"},{"issue":"474","key":"e_1_2_9_25_1","first-page":"e6","article-title":"Androgen receptor pathway\u2010independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn EG","year":"2017","journal-title":"Cancer Cell"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm501239f"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506859"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.3101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.3101","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T13:30:20Z","timestamp":1734701420000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.3101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1002\/cam4.3101"],"URL":"https:\/\/doi.org\/10.1002\/cam4.3101","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"2020-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}